• Magda Blessmann WeberEmail author
  • Fernanda Oliveira Camozzato


Pruritus is a frequent symptom in the general population and can occur in many skin and systemic diseases. Its frequency demonstrates a high burden and an impaired quality of life. According to the International Forum on the Study of Itch (IFSI) the classification comprises a clinical distinction of patients with pruritus on primarily diseased/inflamed skin, pruritus on normal skin and pruritus with chronic secondary scratch lesions. The pruritus must be considered as a symptom and not a disease because an underlying cause can be identified in the medical investigation and follow-up of the patient. As a consequence of the diversity of possible underlying diseases, no single therapy concept can be recommended.


Pruritus Itch Chronic pruritus Acute pruritus Mediators Neural pathways Pathophysiology Clinical classification Skin diseases Systemic disease Symptomatic therapy Systemic therapy 



Amyelinic C fibers 

One of three classes of nerve fiber in the central nervous system and peripheral nervous system. There are a myriad of mediators capable of stimulating these afferent nerves leading to itch, including biogenic amines, proteases, cytokines, and peptides. Some of these mediators can also evoke sensations of pain, and the sensory processing underlying both sensations overlaps in complex ways.


An active component of chili peppers, which are plants belonging to the genus Capsicum. Capsaicin is used to help relieve a certain type of pain known as neuralgia.

JAK2V617 mutation 

The JAK2V617 mutated allele is present in virtually all patients with polycythemia vera (PV) and in about 60% of those with essential thrombocythemia (ET) and primary myelofibrosis (PMF), which are the other two main clinical entities included within the group of myeloproliferative neoplasms. The presence of the mutation, and/or the burden of JAK2V617 allele, has been found to correlate with defined laboratory abnormalities and clinical features in the different myeloproliferative neoplasms.


  1. 1.
    Hafenreffer S. De pruritu, in Nosodochium, in quo cutis, eique adharetium partuim, affectus omnes, singulari methodo, et cognoscendi et curandi fidelissime traduntur. Ulm, B Kühn, 1660, p. 98–102. Apud Wahlgren C-F. Measuremento of Itch. Seminars in Dermatol. 1995;14(4):277–84.Google Scholar
  2. 2.
    Etter L, Myers SA. Pruritus in systemic disease: mechanisms and management. Dermatol Clin. 2002;20(3):459–72.PubMedPubMedCentralCrossRefGoogle Scholar
  3. 3.
    Twycross R, Greaves MW, Handwerker H, Jones EA, Libretto SE, Szepietowski, et al. Itch: scratching more than the surface. QJM. 2003;96(1):7–26.PubMedPubMedCentralCrossRefGoogle Scholar
  4. 4.
    LaMotte RH. Subpopulations of “nocifensor neurons” contributing to pain and allodynia, itch and alloknesis. Am Pain Soc J. 1992;1:115–26.Google Scholar
  5. 5.
    Ständer S, Weisshaar E, Mettang T, Szepietowski JC, Carstens E, Ikoma A, et al. Clinical classification of itch: a position paper of the international forum for the study of itch. Acta Derm Venereol. 2007;87:291–4.PubMedPubMedCentralCrossRefGoogle Scholar
  6. 6.
    Yosipovitch G, Greaves M, Schmelz M. Itch. Lancet. 2003;361:690–4.PubMedPubMedCentralCrossRefGoogle Scholar
  7. 7.
    Yamamoto Y, Yamazaki S, Hayashino Y, et al. Association between frequency of pruritic symptoms and perceived psychological stress: a Japanese population based study. Arch Dermatol. 2009;145:1384–8.PubMedPubMedCentralCrossRefGoogle Scholar
  8. 8.
    Adler HM. Might a psychosocial approach improve our understanding of itching and scratching? Int J Dermatol. 2003;42:160–3.PubMedPubMedCentralCrossRefGoogle Scholar
  9. 9.
    Dalgard F, Svensson A, Holm JO, Sundby J. Self-reported skin morbidity in Oslo. Associations with sociodemographic factors among adults in a cross-sectional study. Br J Dermatol. 2004;151:452–7.PubMedPubMedCentralCrossRefGoogle Scholar
  10. 10.
    Matterne U, Apfelbacher CJ, Loerbroks A, et al. Prevalence, correlates and characteristics of chronic pruritus: a population based cross-sectional study. Acta Derm Venereol. 2011;91:674–9.PubMedPubMedCentralCrossRefGoogle Scholar
  11. 11.
    Stander S, Stumpf A, Osada N, Wilp S, Chatzigeorgakidis E, Pfeiderer B. Gender differences in chronic pruritus: women present different morbidity, more scratch lesions and higher burden. Br J Dermatol. 2013;168(6):1273–80. (Epub ahead of print).PubMedPubMedCentralCrossRefGoogle Scholar
  12. 12.
    Stander S, Schäfer I, Phan NQ, et al. Prevalence of chronic pruritus in Germany: results of a cross-sectional study in a sample working population of 11,730. Dermatology. 2010;221:229–35.Google Scholar
  13. 13.
    Weisshaar E, Dalgard F. Epidemiology of itch: adding to the burden of skin morbidity. Acta Derm Venereol. 2009;89:339–50.PubMedPubMedCentralCrossRefGoogle Scholar
  14. 14.
    Dalgard F, Dawn AG, Yosipovitch G. Are itch and chronic pain associated in adults? Results of a large population survey in Norway. Dermatology. 2007;214:305–9.PubMedPubMedCentralCrossRefGoogle Scholar
  15. 15.
    Wolkenstein P, Grob JJ, Bastuji-Garin S, Ruszczynski S, Roujeau JC, Revuz J. French people and skin diseases: results of a survey using a representative sample. Arch Dermatol. 2003;139:1614–9.PubMedGoogle Scholar
  16. 16.
    Britt H, Pan Y, Miller GC, Valenti L, Charles J, Knox S, et al. Presentations of ‘itch’ in Australian general practice. Aust Fam Physician. 2004;33:488.PubMedPubMedCentralGoogle Scholar
  17. 17.
    McCormick A, Fleming D, Charlton J. Morbidity statistics from general practice. Fourth national study 1991–1992. London: Her Majestic’s Stationery Office; 1995.Google Scholar
  18. 18.
    Szepietowski JC, Salomon J. Uremic pruritus: still an important clinical problem. J Am Acad Dermatol. 2004;51:842–3.PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    Yosipovitch G, Goon AT, Wee J, Chan YH, Zucker I, Goh CL. Itch characteristics in Chinese patients with atopic dermatitis using a new questionnaire for the assessment of pruritus. Int J Dermatol. 2002;41:212–6.PubMedPubMedCentralCrossRefGoogle Scholar
  20. 20.
    Ikoma A, Steinhoff M, Ständer S, Yosipovitch G, Schmelz M. The neurobiology of itch. Nat Rev Neurosci. 2006;7:535–47.Google Scholar
  21. 21.
    LaMotte RH, Dong X, Ringkamp M. Sensory neurons and circuits mediating itch. Nat Neurosci. 2014;15:19–31.CrossRefGoogle Scholar
  22. 22.
    Davidson S, Giesler GJ. The multiple pathways for itch and their interactions with pain. Trends Neurosci. 2010;33:550–8.PubMedPubMedCentralCrossRefGoogle Scholar
  23. 23.
    Hyndman OR, Wolkin J. Anterior cordotomy: further observations on the physiologic results and optimum manner of performance. Arch Neurol Psychiatr. 1943;50:129–48.CrossRefGoogle Scholar
  24. 24.
    Davidson S, et al. The itch-producing agents histamine and cowhage activate separate populations of primate spinothalamic tract neurons. J Neurosci. 2007;27:10007–14.PubMedPubMedCentralCrossRefGoogle Scholar
  25. 25.
    Davidson S, et al. Pruriceptive spinothalamic tract neurons: physiologic properties and projection targets in the primate. J Neurophysiol. 2012;108:1711–23.PubMedPubMedCentralCrossRefGoogle Scholar
  26. 26.
    Han L, Ma C, Liu Q, Weng H-J, Cui Y, et al. A subpopulation of nociceptors specifically linked to itch. Nat Neurosci. 2013;16:174–82.PubMedPubMedCentralCrossRefGoogle Scholar
  27. 27.
    Han SK, Mancino V, Simon MI. Phospholipase Cβ 3 mediates the scratching response activated by the histamine H1 receptor on C-fiber nociceptive neurons. Neuron. 2006;52:691–703.PubMedPubMedCentralCrossRefGoogle Scholar
  28. 28.
    Huang JF, Thurmond R. The new biology of histamine receptors. Curr Allergy Asthma Rep. 2008;8:21–7.PubMedPubMedCentralCrossRefGoogle Scholar
  29. 29.
    Greaves MW, Wall PD. Pathophysiology of itching. Lancet. 1996;348:938–40.PubMedPubMedCentralCrossRefGoogle Scholar
  30. 30.
    Weisshaar E, Ziethen B, Rohl FW, Gollnick H. The antipruritic effect of a 5HT3 receptor antagonist (tropisetron) is dependent on mast cell depletion: an experimental study. Exp Dermatol. 1999;8:254–60.PubMedPubMedCentralCrossRefGoogle Scholar
  31. 31.
    Cocchiara R, Lampiasi N, Albeggiani G, Bongiovanni A, Azzolina A, Geraci D. Mast cell production of TNF-alpha induced by substance P: evidence for a modulatory role of substance P-antagonists. J Neuroimmunol. 1999;101:128–36.PubMedPubMedCentralCrossRefGoogle Scholar
  32. 32.
    Toyoda M, Nakamura M, Makino T, Hino T, Kaqoura M, Morohashi M. Nerve growth factor and substance P are useful plasma markers of disease activity in atopic dermatitis. Br J Dermatol. 2002;147:71–9.PubMedPubMedCentralCrossRefGoogle Scholar
  33. 33.
    Costa SK, Starr A, Hyslop S, Gilmore D, Bran SD. How important are NK1 receptors for influencing microvascular inflammation and itch in the skin? Studies using Phoneutria nigriventor venom. Vasc Pharmacol. 2006;45:209–14.CrossRefGoogle Scholar
  34. 34.
    Nolano M, Simone DA, Wendelschafer-Crabb G, Johnson T, Hazen E, Kennedy WR. Topical capsaicin in humans: parallel loss of epidermal nerve fibres and pain sensation. Pain. 1999;81:135–45.PubMedPubMedCentralCrossRefGoogle Scholar
  35. 35.
    Hagermark O, Strandberg K. Pruritogenic activity of prostaglandin E2. Acta Derm Venereol. 1977;57:37–43.PubMedPubMedCentralGoogle Scholar
  36. 36.
    Greaves MW, McDonald-Gibson W. Itch: role of prostaglandins. Br Med J. 1973;3:608–9.PubMedPubMedCentralCrossRefGoogle Scholar
  37. 37.
    Gaspari AA, Lotze MT, Rosenberg SA, Stern JB, Katz SI. Dermatologic changes associated with interleukin 2 administration. JAMA. 1987;258:1624–9.PubMedPubMedCentralCrossRefGoogle Scholar
  38. 38.
    Wahlgren CF, Tenvall Linder M, Hagermark O, Scheynius A. Itch and inflammation induced by intradermally injected interleukin-2 in atopic dermatitis patients and healthy subjects. Arch Dermatol Res. 1995;287:572–80.PubMedPubMedCentralCrossRefGoogle Scholar
  39. 39.
    Neis MM, Peters B, Dreuw A, Wenzel J, Bieber T, Mauch C, et al. Enhanced expression levels of IL-31 correlate with IL-4 and IL-13 in atopic and allergic contact dermatitis. J Allergy Clin Immunol. 2006;118:930–7.PubMedPubMedCentralCrossRefGoogle Scholar
  40. 40.
    Heyer G, Dotzer M, Diepgen TL, Handwerker HO. Opiate and H1 antagonist effects on histamine induced pruritus and alloknesis. Pain. 1997;73:239–43.PubMedPubMedCentralCrossRefGoogle Scholar
  41. 41.
    Saiah M, Borgeat A, Wilder-Smith OH, Rifat K, Suter PM. Epidural morphine induced pruritus: propofol vs naloxone. Anesth Analg. 1994;78:1110–3.PubMedPubMedCentralCrossRefGoogle Scholar
  42. 42.
    Umeuchi H, Togashi Y, Honda T, Nakao K, Okano K, Tanaka T, et al. Involvement of central mu-opioid system in the scratching behavior in mice and the suppression of it by the activation of kappa-opioid system. Eur J Pharmacol. 2003;477:29–35.PubMedPubMedCentralCrossRefGoogle Scholar
  43. 43.
    Steinhoff M, Neisius U, Ikoma A, Fartasch M, Heyer G, Skov PS, et al. Proteinase-activated receptor-2 mediates itch: a novel pathway for pruritus in human skin. J Neurosci. 2003;23:6176–80.PubMedPubMedCentralCrossRefGoogle Scholar
  44. 44.
    Peier AM, Reeve AJ, Andersson DA, Moqrich A, Earley TJ, Hergarden AC, et al. A heat-sensitive TRP channel expressed in keratinocytes. Science. 2002;296:2046–9.PubMedPubMedCentralCrossRefGoogle Scholar
  45. 45.
    Ständer S, Moormann C, Schumacher M, Buddenkotte J, Artuc M, Shpacovitch V, et al. Expression of vanilloid receptor subtype 1 in cutaneous sensory nerve fibers, mast cells, and epithelial cells of appendage structures. Exp Dermatol. 2004;13:129–39.PubMedPubMedCentralCrossRefGoogle Scholar
  46. 46.
    Stokes AJ, Shimoda LM, Koblan-Huberson M, Adra CN, Turner H. A TRPV2-PKA signaling module for transduction of physical stimuli in mast cells. J Exp Med. 2004;200:137–47.PubMedPubMedCentralCrossRefGoogle Scholar
  47. 47.
    Peier AM, Moqrich A, Hergarden AC, Reeve AJ, Andersson DA, Story GM, et al. ATRP channel that senses cold stimuli and menthol. Cell. 2002;108:705–15.PubMedPubMedCentralCrossRefGoogle Scholar
  48. 48.
    Aloe L. Rita Levi-Montalcini: the discovery of nerve growth factor and modern neurobiology. Trends Cell Biol. 2004;14:395–9.PubMedPubMedCentralCrossRefGoogle Scholar
  49. 49.
    Groneberg DA, Serowka F, Peckenschneider N, Artuc M, Grutzkau A, Fischer A, et al. Gene expression and regulation of nerve growth factor in atopic dermatitis mast cells and the human mast cell line-1. J Neuroimmunol. 2005;161:87–92.PubMedPubMedCentralCrossRefGoogle Scholar
  50. 50.
    Dvorak M, Watkinson A, McGlone F, Rukwied R. Histamine induced responses are attenuated by cannabinoid receptor agonist in human skin. Inflamm Res. 2003;52:238–45.PubMedPubMedCentralCrossRefGoogle Scholar
  51. 51.
    Theoharides TC, Singh LK, Boucher W, Pang X, Letourneau R, Webster E, et al. Corticotropin-releasing hormone induces skin mast cell degranulation and increased vascular permeability, a possible explanation for its proinflammatory effects. Endocrinology. 1998;139:403–13.PubMedPubMedCentralCrossRefGoogle Scholar
  52. 52.
    Zabawski EJ Jr, Kahn MA, Gregg LJ. Treatment of atopic dermatitis with zafirlukast. Dermatol Online J. 1999;5:10.PubMedPubMedCentralGoogle Scholar
  53. 53.
    Weidner C, Klede M, Rukwied R, Lischetzki G, Neisius U, Skov PS, et al. Acute effects of substance P and calcitonin gene-related peptide in human skin – a microdialysis study. J Invest Dermatol. 2000;115:1015–20.PubMedPubMedCentralCrossRefGoogle Scholar
  54. 54.
    MiyamotoT NH, Kuraishi Y. Intradermalcholinergic agonists induce itch-associated response via M3 muscarinic acetylcholine receptors in mice. Jpn J Pharmacol. 2002;88:351–4.CrossRefGoogle Scholar
  55. 55.
    Rukwied R, Lischetzki G, McGlone F, Heyer G, Schmelz M. Mast cell mediators other than histamine induce pruritus in atopic dermatitis: a dermal microdialysis study. Br J Dermatol. 2000;142:1–8.CrossRefGoogle Scholar
  56. 56.
    Zirvas MJ, Seraly MP. Pruritus of unknown origin: a retrospective study. J Am Acad Dermatol. 2001;45:892–6.CrossRefGoogle Scholar
  57. 57.
    Urbonas A, Schwartz RA, Szepietowski JC. Uremic pruritus – an update. Am J Nephrol. 2001;21(5):343–50.PubMedPubMedCentralCrossRefGoogle Scholar
  58. 58.
    Mettang T, Pauli-Magnus C, Alscher DM. Uraemic pruritus new perspectives and insights from recent trials. Nephrol Dial Transplant. 2002;17:1558–63.PubMedPubMedCentralCrossRefGoogle Scholar
  59. 59.
    Szepitowski JC, Morita A, Tsuji T. Ultraviolet B induces mast cell apoptosis: a hypotjetical mechanism of ultraviolet B treatment for uremic pruritus. Med Hypotheses. 2002;58(2):167–70.CrossRefGoogle Scholar
  60. 60.
    Murphy M, Reaich D, Pai P, Finn P, Carmichael AJ. A randomized, placebo-controlled, double-blind trial of andonsetron in renal itch. Br J Dermatol. 2003;148:314–7.PubMedPubMedCentralCrossRefGoogle Scholar
  61. 61.
    Szepitowski JC, Schwartz RA. Uremic pruritus. Int J Dermatol. 1998;37:247–53.CrossRefGoogle Scholar
  62. 62.
    Bergasa NV. The pruritus of cholestasis. J Hepatol. 2005;43:1078–88.PubMedPubMedCentralCrossRefGoogle Scholar
  63. 63.
    Cacoub P, Poynard T, Ghillani P, Charlotte F, Olivi M, Piette JC, et al. Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC group. Multidepartment virus C. Arthritis Rheum. 1999;42:2204–12.PubMedPubMedCentralCrossRefGoogle Scholar
  64. 64.
    Bergasa NV, Mehlman JK, Jones EA. Pruritus and fatigue in primary biliary cirrhosis. Baillieres Best Pract Res Clin Gastroenterol. 2000;14:643–55.PubMedPubMedCentralCrossRefGoogle Scholar
  65. 65.
    Bolier R, Oude Elferink RPJ, Beuers U. Advances in pathogenesis and treatment of pruritus. Clin Liver Dis. 2013;17:319–29.PubMedPubMedCentralCrossRefGoogle Scholar
  66. 66.
    Kremer AE, Dijk RV, Leckie P, Schaap FG, Kuiper EM, Mettang T, et al. Serum autotaxin is increased in pruritus of cholestasis, but not of other origin and responds to therapeutic interventions. Hepatology. 2012;56:1391. (Epub ahead of print).PubMedPubMedCentralCrossRefGoogle Scholar
  67. 67.
    Zylicz Z, Twycross R, Jones EA. Pruritus in advanced disease. Oxford: Oxford University Press; 2004.CrossRefGoogle Scholar
  68. 68.
    Krajnik M, Zylicz Z. Pruritus in advanced internal diseases. Pathog Treat Neth J Med. 2001;58:27–40.CrossRefGoogle Scholar
  69. 69.
    Weisshaar E, Kucenic MJ, Fleischer Jr AB, Bhard JD. Pruritus and dysesthesia. In: Bolognia JL, Jorizzo J, Rapini RP, editors. Spain: Dermatology. Mosby; 2015. p. 95–110.Google Scholar
  70. 70.
    Diehn F, Tefferi A. Pruritus in polycythaemia vera: prevalence, laboratory correlates and management. Br J Haematol. 2001;115:619–21.PubMedPubMedCentralCrossRefGoogle Scholar
  71. 71.
    Pieri L, Bogani C, Guglielmelli P, Zingariello M, Rana RA, Bartalucci N, et al. The JAK2V617 mutation induces constitutive activation and agonist hypersensitivity in basophils from patients with polycythemia vera. Haematologica. 2009;94:1537–45.PubMedPubMedCentralCrossRefGoogle Scholar
  72. 72.
    Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105:3768–85.PubMedPubMedCentralCrossRefGoogle Scholar
  73. 73.
    Bowen GM, Stevens SR, Dubin HV, Siddiqui J, Cooper KD. Diagnosis of Sezary syndrome in a patient with generalized pruritus based on early molecular study and flow cytometry. J Am Acad Dermatol. 1995;33:678–80.PubMedPubMedCentralCrossRefGoogle Scholar
  74. 74.
    Pujol RM, Gallardo F, Llistosella E, et al. Invisible mycosis fungoides: a diagnostic challenge. J Am Acad Dermatol. 2002;47:S168–71.PubMedPubMedCentralCrossRefGoogle Scholar
  75. 75.
    Tobias Görge, Meinhard Schiller. Chapter 18 Cutaneous T-cell lymphoma. Misery L, Ständer S, editors. Pruritus. London: Springer-Verlag London Limited; 2010. p. 121–4.Google Scholar
  76. 76.
    Jabbour SA. Cutaneous manifestations of endocrine disorders: a guide for dermatologists. Am J Clin Dermatol. 2003;4:315–31.PubMedPubMedCentralCrossRefGoogle Scholar
  77. 77.
    Caravati CM Jr, Richardson DR, Wood BT, Cawley EP. Cutaneous manifestations of hyperthyroidism. South Med J. 1969;62:1127–30.PubMedPubMedCentralCrossRefGoogle Scholar
  78. 78.
    Neilly JB, Martin A, Simpson N, MacCuish AC. Pruritus in diabetes mellitus: investigation of prevalence and correlation with diabetes control. Diabetes Care. 1986;9:273–5.PubMedPubMedCentralCrossRefGoogle Scholar
  79. 79.
    Goodkin R, Wingard E, Bernhard JD. Brachioradial pruritus: cervical spine disease and neurogenic/neurogenic pruritus. J Am Acad Dermatol. 2003;48(4):521–4.PubMedPubMedCentralCrossRefGoogle Scholar
  80. 80.
    Gelfand JM, Rudikoff D. Evaluation and treatment of itching in HIV-infected patients. Mt Sinai J Med. 2001;68(4–5):298–308.PubMedPubMedCentralGoogle Scholar
  81. 81.
    Eisman S. Pruritic papular eruption in HIV. Dermatol Clin. 2006;24:449–57.PubMedPubMedCentralCrossRefGoogle Scholar
  82. 82.
    Daniel GL, Longo WE, Vernava AM III. Pruritus ani. Causes and concerns. Dis Colon Rectum. 1994;37:670–4.PubMedPubMedCentralCrossRefGoogle Scholar
  83. 83.
    Reich A, Ständer S. Drug-induced pruritus: a review. Acta Derm Venereol. 2009;89:236–44.PubMedPubMedCentralCrossRefGoogle Scholar
  84. 84.
    Kaplan AP. Drug-induced skin disease. J Allergy Clin Immunol. 1984;74:573–9.PubMedPubMedCentralCrossRefGoogle Scholar
  85. 85.
    Weisshaar E, Szepietowski JC, Darsow U, et al. European guideline on chronic pruritus. Acta Derm Venereol. 2012;92:563–81.PubMedPubMedCentralCrossRefGoogle Scholar
  86. 86.
    Yosipovitch G, Bernhard JD. Chronic pruritus. N Engl J Med. 2013;368:1625–34. 17 april 25.PubMedPubMedCentralCrossRefGoogle Scholar
  87. 87.
    Yosipovitch G, David M. The diagnosis and therapeutic approach to idiopatic generalized pruritus. Int J Dermatol. 1999;38:881–7.PubMedPubMedCentralCrossRefGoogle Scholar
  88. 88.
    Weisshaar E, Kucenic MJ, Fleischer AB. Pruritus: a review. Acta Derm Venereol. 2003;213(Suppl):5–32.Google Scholar
  89. 89.
    Ständer S, Streit M, Darsow U, et al. Diagnostic and therapeutic measures in chronic pruritus. J Dtsch Dermatol Ges. 2006;4:350–70.PubMedPubMedCentralCrossRefGoogle Scholar
  90. 90.
    Sommer F, Hensen P, Böckenholt B, et al. Underlying diseases and cofactors in patients with severe chronic pruritus: a 3-year retrospective study. Acta Derm Venereol. 2007;87:510–6.PubMedPubMedCentralCrossRefGoogle Scholar
  91. 91.
    Bingham LG, Noble JW, Davis MD. Wet dressings used with topical corticosteroids for pruritic dermatoses: a retrospective study. J Am Acad Dermatol. 2009;60:792–800.PubMedPubMedCentralCrossRefGoogle Scholar
  92. 92.
    Ali SM, Yosipovitch G. Skin pH: from basic science to basic skin care. Acta Derm Venereol. 2013;93:261. (Epub ahead of print).PubMedPubMedCentralCrossRefGoogle Scholar
  93. 93.
    Papoiu AD, Yosipovitch G. Topical capsaicin: the fire of a “hot” medicine is reignited. Expert Opin Pharmacother. 2010;11:1359–71.PubMedPubMedCentralCrossRefGoogle Scholar
  94. 94.
    Patel T, Ishiuji Y, Yosipovitch G. Menthol: a refreshing look at this ancient compound. J Am Acad Dermatol. 2007;57:873–8.PubMedPubMedCentralCrossRefGoogle Scholar
  95. 95.
    Young TA, Patel TS, Camacho F, et al. A pramoxine-based anti-itch lotion is more effective than a control lotion for the treatment of uremic pruritus in adult hemodialysis patients. J Dermatolog Treat. 2009;20:76–81.PubMedPubMedCentralCrossRefGoogle Scholar
  96. 96.
    Suys E. Randomized study of topical tacrolimus ointment as possible treatment for resistant idiopathic pruritus ani. J Am Acad Dermatol. 2012;66:327–8.PubMedPubMedCentralCrossRefGoogle Scholar
  97. 97.
    Drake LA, Fallon JD, Sober A. Relief of pruritus in patients with atopic dermatitis after treatment with topical doxepin cream. J Am Acad Dermatol. 1994;31:613–6.PubMedPubMedCentralCrossRefGoogle Scholar
  98. 98.
    O’Donoghue M, Tharp MD. Antihistamines and their role as antipruritics. Dermatol Ther. 2005;18:333–40.PubMedPubMedCentralCrossRefGoogle Scholar
  99. 99.
    Gunal AI, Ozalp G, Yoldas TK, Gunal SY, Kirciman E, Celiker H. Gabapentin therapy for pruritus in haemodialysis patients: a randomized, placebo-controlled, double-blind trial. Nephrol Dial Transplant. 2004;19:3137–9.PubMedPubMedCentralCrossRefGoogle Scholar
  100. 100.
    Phan NQ, Bernhard JD, Luger TA, Ständer S. Antipruritic treatment with systemic μ-opioid receptor antagonists: a review. J Am Acad Dermatol. 2010;63:680–8.Google Scholar
  101. 101.
    Kumagai H, Ebata T, Takamori K, Muramatsu T, Nakamoto H, Suzuki H. Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients: a phase III, randomized, double-blind, placebo-controlled study. Nephrol Dial Transplant. 2010;25:1251–7.PubMedPubMedCentralCrossRefGoogle Scholar
  102. 102.
    Wikström B, Gellert R, Ladefoged SD, et al. Kappa-opioid system in uremic pruritus: multicenter, randomized, double blind, placebo-controlled clinical studies. J Am Soc Nephrol. 2005;16:3742–7.PubMedPubMedCentralCrossRefGoogle Scholar
  103. 103.
    Peer G, Kivity S, Agami O, et al. Randomised crossover trial of naltrexone in uraemic pruritus. Lancet. 1996;348:1552–4.PubMedPubMedCentralCrossRefGoogle Scholar
  104. 104.
    Pauli-Magnus C, Mikus G, Alscher DM, et al. Naltrexone does not relieve uremic pruritus: results of a randomized, double-blind, placebo-controlled crossover study. J Am Soc Nephrol. 2000;11:514–9.PubMedPubMedCentralGoogle Scholar
  105. 105.
    Dawn AG, Yosipovitch G. Butorphanol for treatment of intractable pruritus. J Am Acad Dermatol. 2006;54:527–31.PubMedPubMedCentralCrossRefGoogle Scholar
  106. 106.
    Ständer S, Böckenholt B, Schürmeyer-Horst F, et al. Treatment of chronic pruritus with the selective serotonin re-uptake inhibitors paroxetine and fluvoxamine: results of an open-labelled, two-arm proof of concept study. Acta Derm Venereol. 2009;89:45–51.Google Scholar
  107. 107.
    Mayo MJ, Handem I, Saldana S, Jacobe H, Getachew Y, Rush AJ. Sertraline as a first-line treatment for cholestatic pruritus. Hepatology. 2007;45:666–74.PubMedPubMedCentralCrossRefGoogle Scholar
  108. 108.
    Hundley JL, Yosipovitch G. Mirtazapine for reducing nocturnal itch in patients with chronic pruritus: a pilot study. J Am Acad Dermatol. 2004;50:889–91.PubMedPubMedCentralCrossRefGoogle Scholar
  109. 109.
    Demierre MF, Taverna J. Mirtazapine and gabapentin for reducing pruritus in cutaneous T-cell lymphoma. J Am Acad Dermatol. 2006;55:543–4.PubMedPubMedCentralCrossRefGoogle Scholar
  110. 110.
    Suchin KR. Pruritus of unknown etiology including senile pruritus. In: Lebwohl M, Heymann WR, Berth-Jones J, Coulson I, editors. Treatment of skin disease – comprehensive therapeutic strategies. Mosby: EUA; 2002. p. 519–22.Google Scholar
  111. 111.
    Prince MI, Burt AD, Jones DEJ. Hepatitis and liver dysfunction with rifampicin therapy for pruritus in primary biliary cirrhosis. Gut. 2002;50:436–9.PubMedPubMedCentralCrossRefGoogle Scholar
  112. 112.
    Suchin KR, Suchin EJ. Pruritus of renal and liver disease. In: Lebwohl M, Heymann WR, Berth-Jones J, Coulson I editors. Treatment of skin disease – comprehensive therapeutic strategies. Mosby: EUA; 2002. p. 515–8.Google Scholar
  113. 113.
    Daly BM, Shuster S. Antipruritic action of thalidomide. Acta Derm Venereol. 2000;80:24–5.PubMedPubMedCentralCrossRefGoogle Scholar
  114. 114.
    Moraes M, Russo G. Thalidomide and its dermatologic uses. Am J Med Sci. 2001;321(5):321–6.PubMedPubMedCentralCrossRefGoogle Scholar
  115. 115.
    Rivard J, Lim HW. Ultraviolet phototherapy for pruritus. Dermatol Ther. 2005;18:344–54.PubMedPubMedCentralCrossRefGoogle Scholar
  116. 116.
    Gilchrest BA, Rowe JW, Brown RS, Steinman TI, Arndt KA. Ultraviolet phototherapy of uremic pruritus: long-term results and possible mechanism of action. Ann Intern Med. 1979;91:17–21.PubMedPubMedCentralCrossRefGoogle Scholar
  117. 117.
    Ko MJ, Yang JY, Wu HY, et al. Narrowband ultraviolet B phototherapy for patients with refractory uraemic pruritus: a randomized controlled trial. Br J Dermatol. 2011;165:633–9.PubMedPubMedCentralCrossRefGoogle Scholar
  118. 118.
    Hassan I, Haji MI. Understanding itch: an update on mediators and mechanisms of pruritus. Indian J Dermatol Venereol Leprol. 2014;80:106–14.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2018

Authors and Affiliations

  • Magda Blessmann Weber
    • 1
    Email author
  • Fernanda Oliveira Camozzato
    • 2
  1. 1.Dermatology Service of Federal University of Health Sciences of Porto AlegrePorto AlegreBrazil
  2. 2.Brazilian Center for Studies in DermatologyPorto AlegreBrazil

Personalised recommendations